1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Pancreatic Ductal Adenocarcinoma-Pipeline Insights, 2014

SUMMARY
DelveInsight’s,“ Pancreatic Ductal Adenocarcinoma-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Pancreatic Ductal Adenocarcinoma. This report provides information on the therapeutic development based on the Pancreatic Ductal Adenocarcinoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.
Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.

Scope
- The report provides a snapshot of the global therapeutic landscape of Pancreatic Ductal Adenocarcinoma
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Pancreatic Ductal Adenocarcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Pancreatic Ductal Adenocarcinoma and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


Reasons to buy
- Complete Pipeline intelligence and complete understanding over therapeutics development for Pancreatic Ductal Adenocarcinoma
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Pancreatic Ductal Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Table Of Contents

Pancreatic Ductal Adenocarcinoma-Pipeline Insights, 2014
Table of Contents
- Pancreatic Ductal Adenocarcinoma Overview
- Pancreatic Ductal Adenocarcinoma Pipeline Therapeutics
- Pancreatic Ductal Adenocarcinoma Therapeutics under Development by Companies
- Pancreatic Ductal Adenocarcinoma Late Stage Products (Filed and Phase III)
- Comparative Analysis
- Pancreatic Ductal Adenocarcinoma Mid Clinical Stage Products (Phase II)
- Comparative Analysis
- Pancreatic Ductal Adenocarcinoma Early Clinical Stage Products (Phase I and IND Filed)
- Comparative Analysis
- Pancreatic Ductal Adenocarcinoma Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Pancreatic Ductal Adenocarcinoma - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pancreatic Ductal Adenocarcinoma - Discontinued Products
- Pancreatic Ductal Adenocarcinoma - Dormant Products
- Companies Involved in Therapeutics Development for Pancreatic Ductal Adenocarcinoma
- Appendix
- Methodology
- Contact Us
- Disclaimer

List of Tables

- Number of Products under Development for Pancreatic Ductal Adenocarcinoma, 2014
- Number of Products under Development by Companies
- Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2014
- Comparative Analysis Mid Clinical Stage Products (Phase II), 2014
- Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2014
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2014
- Drug Candidates Profiles
- Pancreatic Ductal Adenocarcinoma Assessment by Monotherapy Products
- Pancreatic Ductal Adenocarcinoma Assessment by Combination Products
- Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
- Pancreatic Ductal Adenocarcinoma Assessment by Stage and Route of Administration
- Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
- Pancreatic Ductal Adenocarcinoma Assessment by Stage and Molecule Type
- Pancreatic Ductal Adenocarcinoma Therapeutics - Discontinued Products
- Pancreatic Ductal Adenocarcinoma Therapeutics - Dormant Products
- Products under Development by Companies, 2014

List of Figures

- Number of Products under Development for Pancreatic Ductal Adenocarcinoma, 2014
- Late Clinical Stage Products (Filed and Phase III), 2014
- Mid Clinical Stage Products (Phase II), 2014
- Early Clinical Stage Products (Phase I and IND Filed), 2014
- Discovery and Pre-Clinical Stage Products, 2014
- Pancreatic Ductal Adenocarcinoma Assessment by Monotherapy Products
- Pancreatic Ductal Adenocarcinoma Assessment by Combination Products
- Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
- Pancreatic Ductal Adenocarcinoma Assessment by Stage and Route of Administration
- Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
- Pancreatic Ductal Adenocarcinoma Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

Lung Cancer Surgery Market by Procedure, Minimally Invasive, Device, Monitoring, Endoscopic Instrument - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The lung cancer surgery market is projected to reach USD 29.99 billion by 2021 from USD 21.58 billion in 2016, at a CAGR of 6.8% from 2016 to 2021. The global lung cancer surgery market is segmented based ...

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

Circulating Tumor Cell, Cell Free DNA and Exosome/Microvesicle Cancer Diagnostics by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and ...

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

Liquid Biopsy Markets by Lung, Breast, Colorectal, Prostate and Other. 2017-2020 Including Screening Market Potential Size with Executive and Consultant Guides

  • $ 5495
  • Industry report
  • March 2017
  • by Howe Sound Research

“Blood Tests replace Surgical Biopsies. Single screening test for all cancers announced .....” The Diagnostic, Monitoring and Screening Test opportunities are explored. A revolution in cancer diagnostics ...


Download Unlimited Documents from Trusted Public Sources

Lymphoma Statistics in Germany

  • March 2017
    167 pages
  • Lymphoma  

    Cancer  

    Leukemia  

  • Germany  

    Europe  

    United States  

View report >

Hospital Statistics in the US

  • March 2017
    16 pages
  • Hospital  

    Breast Cancer  

  • United States  

View report >

Colorectal Cancer Statistics in Norway and the US

  • March 2017
    6 pages
  • Colorectal Canc...  

    Cancer  

    Therapy  

  • United States  

    Norway  

View report >

Related Market Segments :

Lung Cancer

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.